American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients

Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis

doi:10.1016/j.jtct.2020.10.003

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients

Transplant Cell Ther. 2021 Mar;27(3):201-211. doi: 10.1016/j.jtct.2020.10.003.

Authors

Sanjeet S Dadwal¹, Tobias M Hohl², Cynthia E Fisher³, Michael Boeckh⁴, Genofeva Papanicolaou², Paul A Carpenter⁵, Brian T Fisher⁶, Monica A Slavin⁷, D P Kontoyiannis⁸

Affiliations

¹ Division of Infectious Diseases, City of Hope National Medical Center, Duarte, California. Electronic address: sdadwal@coh.org.
² Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Division of Infectious Diseases, University of Washington, Seattle, Washington.
⁴ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁶ Division of Pediatric Infectious Diseases, Children's Hospital of Philadelphia, Pennsylvania.
⁷ Department of Infectious Disease, and National Center for Infections in Cancer, Peter McCallum Cancer Center, Melbourne, Victoria, Australia.
⁸ Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely fresh approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQs), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed, then answered FAQs, and finalized topics with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This second guideline in the series focuses on invasive aspergillosis, a potentially life-threatening infection in the peri-HCT period. The relevant risk factors, diagnostic considerations, and prophylaxis and treatment approaches are reviewed.

Keywords: Antifungal prophylaxis; Antifungal therapy; Diagnosis; Invasive aspergillosis; Transplantation.

Publication types

Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aspergillosis* / diagnosis
Cell- and Tissue-Based Therapy
Child
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Invasive Fungal Infections*
Transplant Recipients
United States

Abstract

Publication types

MeSH terms

Grants and funding